Best Oncology Companies in Belgium
The 45 best Oncology companies in Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AgomAb Therapeutics.
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Is Encouraged to Reach USD 646.33 Billion by 2032
- Oncology Market Value to More Than Double, Reaching USD 748.17 Billion
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Belgium
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | AgomAb Therapeutics Developer of monoclonal antibody molecules for multiple disorders | $327M | 21 mo ago | 23 | Tim Knotnerus CEO | WordPressApple iCloud MailMicrosoft 365+27 | 34 patents MET receptor antibody therapeutics and pancreatic islet cell regeneration technologies | 1 job opening |
| 2 | Biocartis Developer of molecular assays for the detection of various diseases | $305M | 47 mo ago | 43 | — | DrupalApple iCloud MailMicrosoft 365+15 | 225 patents Advanced nucleic acid extraction and multiplex PCR diagnostics for cancer biomarker detection | 2 job openings · 1 launch |
| 3 | PanTera Provider of actinium-225 isotopes for targeted cancer therapy development and production | $140M | 23 mo ago | — | Sven Berghe CEO | WordPressPleskMySQL+15 | 6 patents Production of medical and industrial radioisotopes | 1 job opening · 1 partnership · 1 expansion |
| 4 | Precirix Developer of radiopharmaceuticals for treating cancer | $131M | 53 mo ago | 22 | Ruth Devenyns CEO | Craft CMSPHPYii+11 | 31 patents Pre-targeted cancer radioimmunotherapy using FAP-specific antibody fragments | — |
| 5 | eTheRNA Developer of mRNA-based immunotherapies for cancer and infectious diseases | $104M | 48 mo ago | 80 | Kris Thielemans Founder & CSO | WordPressMySQLPHP+26 | — | 1 partnership |
| 6 | Imcyse Developer of a portfolio of pharmaceuticals against multiple diseases | $57M | 66 mo ago | 48 | Denis Bedoret CEO | — | 216 patents Peptide-based immunomodulatory therapeutics for autoimmune and metabolic diseases | — |
| 7 | ATB Therapeutics Developer of mAb based therapy in oncology | $57M | 21 mo ago | 13 | Bertrand Magy Co-Founder & CEO | UbuntuAnimate.cssReact+10 | 30 patents Plant‑expressed immunotoxin and CD79b‑targeted antibody therapeutics for cancer | — |
| 8 | OncoDNA Theranostic and genomic company for precision medicine in oncology | $45M | 33 mo ago | 37 37 → 46 (+24%) | — | Cart FunctionalityWordPressApple iCloud Mail+38 | 35 patents Personalized cancer neoantigen vaccines and tumor sequencing diagnostics. | — |
| 9 | Volition Developer of cancer diagnostic tests | $40M | 4 mo ago | 104 | Cameron Reynolds CEO | WordPressMySQLPHP+26 | — | 1 launch · 1 partnership |
| 10 | OncoMethylome Diagnostics for early detection of cancer | $34M | 249 mo ago | 3 | — | — | — | — |
| 11 | Galapagos Developer of small molecule drugs for immunology and oncology | $26M | 81 mo ago | 449 449 → 658 (+47%) | Paul Stoffels Md Chief Executive Officer | WordPress Block EditorWordPressApple iCloud Mail+16 | 1,785 patents Small-molecule drugs for inflammatory, autoimmune, infectious, neurodegenerative, and kidney diseases | — |
| 12 | Epics therapeutics Developer of small molecules to treat cancer | $25M | 92 mo ago | 30 30 → 30 (+0%) | Jean Combalbert Founder & CEO | — | 44 patents Small-molecule METTL3 epigenetic writer inhibitors for oncology applications | — |
| 13 | Complix Developer of protein based therapeutics using proprietary alpha-body technology | $24M | 104 mo ago | 13 | Mark Vaeck CEO | WordPressMySQLPHP+20 | 76 patents Design of engineered protein scaffolds (alphabodies) for intracellular targeting and degradation of disease proteins. | — |
| 14 | Convert Pharmaceuticals Developer of small molecule based oncology therapeutics | $17M | 31 mo ago | 2 | Philippe Lambin Co-Founder | — | 6 patents Design and application of novel pharmaceutical prodrugs for improved drug delivery | — |
| 15 | OCTIMET Oncology Developer of MET kinase inhibitors for the treatment of cancer | $12M | 96 mo ago | 1 | — | — | — | — |
| 16 | Celyad Oncology Provider of regenerative therapies for the treatment of cancer and cardiovascular diseases | $10M | 56 mo ago | 32 | Michel Lussier Co-Founder & Chairman | WordPressMySQLPHP+26 | 17 patents Patents concentrated in chemistry & materials | — |
| 17 | Trod Medical Developer of RF-based focal ablation devices for tumor | $7M | 154 mo ago | 1 | — | — | — | — |
| 18 | DeuterOncology Developer of therapeutics for lung cancer | $6M | 43 mo ago | 4 | Timothy Perera Founder & CEO | — | — | — |
| 19 | ElmediX Developer of the device for treating pancreatic cancer | $5M | 54 mo ago | 12 12 → 17 (+42%) | Johan Van Den Bossche Co-founder and president of the board | WordPressMySQLPHP+14 | 38 patents Medical thermal therapy and invasive temperature monitoring devices for hyperthermia treatment | 1 job opening |
| 20 | Biogazelle Transcriptomics-based diagnostics and therapeutics, and qPCR software. | $4M | 79 mo ago | 20 | — | — | 5 patents Patents concentrated in chemistry & materials | — |
| 21 | EsoBiotec Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. | $2M | 32 mo ago | 8 | — | WordPressMySQLPHP+12 | 9 patents Production platforms for viral vectors and producer cell lines in gene therapy | — |
| 22 | Flamingo Developer of RNA-based therapeutics for oncology | $2M | 38 mo ago | 15 | Floor Stam Co-Founder & COO | — | 4 patents Retractable dog leash mechanisms for pet accessory market | — |
| 23 | HistoGeneX Development of predictive biomarkers for cancer treatment through pathology and molecular biology | $2M | 146 mo ago | 150 | — | — | 12 patents Impregnation methods and kits for preparing tissue samples for histopathology and molecular diagnostics | — |
| 24 | Abscint Developer of radiolabelled single domain antibodies to diagnose cancer and cardiac diseases | $1M | 44 mo ago | 2 | Karine Clauwaert CEO | — | — | — |
| 25 | Targetome Developing ADC (antibody-drug conjugates) for the treatment of cancer such as pancreatic cancer. | $393K | 125 mo ago | — | Christophe Van Huffel ex-CEO | — | — | — |
Top 12 Oncology companies in Belgium
#1
Public · Gembloux, Wallonia · founded 1995 · 104 employees$40Mraised▾
Developer of cancer diagnostic tests. The Nu-Q is used for early cancer diagnostics by detecting nucleosome markers of cancer and early-stage cells in the blood. It has also developed vet cancer screening tests.
- Mar 2026Post IPO$2.3M
- May 2025Post IPO$22.6M
- Mar 2024Post IPO$100K
- Dec 2023Post IPO$5.4M
#2
Public · Ghent, Flanders · founded 2017 · 23 employees$327Mraised▾
Developer of monoclonal antibody molecules for multiple disorders. The company has developed the monoclonal antibody molecules called agomAbs which stimulates the molecular and cellular repair mechanisms. It helps in organ function for patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases.
- Oct 2024Series D$89M
- Oct 2023Series C$100M
- Jul 2022Series B$40.5M
- Mar 2021Series B$74M
#3
Series A · Mol, Flanders · founded 2022$139.9Mraised▾
Provider of actinium-225 isotopes for targeted cancer therapy development and production. It focuses on enabling the widespread use of radiopharmaceuticals for personalized tumor treatment. The company aims to secure large-scale production of actinium-225, a promising alpha-emitting radioisotope. Its ultimate goal is to improve the accessibility of innovative cancer therapy based on actinium-225 and theranostics. The company supplies high-purity actinium-225 as an active product ingredient to the global pharmaceutical market.
- Sep 2024Conventional Debt$37.3M
- Sep 2024Series A$102.6M
#4
Series A · Marche en Famenne, Wallonia · founded 2017 · 13 employees$56.9Mraised▾
ATB Therapeutics is developing mAb-based therapy in oncology. The company aims to generate a pipeline of assets for hematological and solid cancers. The company is currently entering in preclinical stage.
- Nov 2024Series A$56.9M
#5
Public · Mechelen, Flanders · founded 2007 · 43 employees$305.3Mraised▾
Developer of molecular assays for the detection of various diseases. The company has developed its proprietary micro-technology platform that is based on integrated molecular and immunodiagnostics technology. It is used for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. It can also be used in the analysis of biomolecules associated with risk factors, early detection, staging, treatment selection, and monitoring of disease.
- Sep 2022Post IPO—
- May 2021Grant (prize money)$1.7M
- Dec 2020Post IPO$181.8M
- Sep 2020Grant (prize money)$1.4M
#6
Series B · Niel, Flanders · founded 2013 · 80 employees$103.9Mraised▾
Developer of mRNA-based immunotherapies for cancer and infectious diseases. It offers proprietary mRNA-based TriMix technology that has three mRNA molecules (caTLR4, CD40L, CD70) boost immune response through the dendritic cell pathway which has applications in indications of Melanoma and breast cancer.
- Aug 2022Series B$38.9M
- Mar 2021Grant (prize money)$7.4M
- Feb 2021Grant (prize money)$6.2M
- Jun 2020Series B$38.2M
#7
Series C · Charleroi, Wallonia · founded 2012 · 37 employees$44.5Mraised▾
Theranostic and genomic company for precision medicine in oncology. The company's biomarker tests include OncoDEEP for precision medicine, OncoSELECT is a liquid biopsy solution for monitoring and therapeutics, and OncoFOLLOW is to monitor the progression of the tumor. Also has NGS interpretation platform OncoKDM for clinical information and biomarker test platform OncoSHARE.
#8
Series B · Brussels, Brussels · founded 2014 · 22 employees$131.1Mraised▾
Developer of radiopharmaceuticals for treating cancer. The company uses camelid single-domain antibody fragments to develop radioligand therapies for multiple targets. The lead product CAM-H2 targets metastatic HER2-positive cancer.
- Mar 2022Series B$87.8M
- Nov 2018Series A$41.8M
- Seed$1.5M
#9
Series A · Liege, Wallonia · founded 2017 · 2 employees$16.7Mraised▾
Convert Pharmaceuticals is involved in the development of small molecule-based oncology therapeutics. The company develops hypoxia-activated cytotoxic small molecules. These therapeutics will act complementary to existing therapies in treatment-resistant areas of solid tumors while maintaining a favorable toxicity profile. The lead drug candidate, CP-506, is a hypoxia-activated prodrug.
- Jan 2024Grant (prize money)$2.7M
- 2023Grant (prize money)$4.5M
- Feb 2018Series A$16.7M
#10
Series B · Liege, Wallonia · founded 2010 · 48 employees$57.3Mraised▾
Developer of a portfolio of pharmaceuticals against multiple diseases. It offers its flagship products for Type 1 diabetes, immune-mediated diseases, oncology among others. It has identified HLA class II/ or Natural killer T -cell epitope to generate antibodies against the immune response promoting diseases. It is also involved in the antigen-based vaccine which contains a specific thioredoxin motif (a few amino acids) and aluminum salts as an adjuvant. The company is running programs in the following disease areas Type 1 Diabetes, Myasthenia Gravis, Viral diseases, and multiple sclerosis. It has completed its phase 1b clinical trial for its drug candidate for type 1 diabetes.
- Feb 2021Series B$25.8M
- Jun 2019Grant (prize money)$5.2M
- Jun 2019Conventional Debt$2.2M
- Jun 2019Series B$31.4M
#11
Series B · Diepenbeek, Flanders · founded 2008 · 13 employees$24.4Mraised▾
Complix is involved in developing alpha-bodies (protein therapeutics) for treating cancer and autoimmune diseases. The company uses its propriety Alpha-bodies to combine their target specificity and affinity with small chemical drugs capability to penetrate cell membranes. The company leading candidate CMX-02 is used in the treatment for severe autoimmune disease and alpha-bodies are active in a variety of tumor cells whilst non-toxic to normal human cells.
- Dec 2017Grant (prize money)$588.3K
- Mar 2015Grant (prize money)$279.6K
- Jun 2013Series B$15.5M
- Oct 2012Grant (prize money)$2.5M
#12
Public · Mont Saint Guibert, Wallonia · founded 2007 · 32 employees$9.6Mraised▾
Celyad is a provider of regenerative therapies for the treatment of cancer and cardiovascular diseases. The company's cardiopoiesis platform is designed to drive the differentiation of multipotent stem cells into new cardiac progenitor cells which the company is using to develop products for heart failure indications. It is developing CYAD-01, a CAR T cells therapy using NK cells receptor and off-the-shelf CAR T-cell products for the treatment of cancer such as Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM). It also has heart access technology that comprises the number of instruments such as heart access sheath, mitral valve neo-chordae, closure device which allow for quick and easy trans-thoracic access to the heart.
- Dec 2021Post IPO$32.5M
- Nov 2019Grant (prize money)$9.5M
- Feb 2015Post IPO$36.2M
- Nov 2013Grant (prize money)$6.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Belgium
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 444 Belgium-affiliated papers.
- Ludwig Cancer Research115
- KU Leuven79
- Ghent University41
- Institut Jules Bordet34
- Vrije Universiteit Brussel27
- Tumor microenvironment9→55
- Immune system3→45
- Immunotherapy2→34
- Cancer research7→33
- Cancer immunotherapy1→24
- Tumor microenvironment13→90
- Immune system10→64
- Immunotherapy9→62
- Cancer research10→56
- Cancer immunotherapy5→21
- Immunotherapy3→30
- Tumor microenvironment2→23
- Cancer immunotherapy2→20
- Immune system3→19
- Cancer research2→11
Where oncology is researched across Belgium
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.